Bookmark and Share

Publications - Malaria

Herrington DA, Clyde DF, Losonsky GL, Cortesia M, Murphy JR, Davis J, Baqar S, Felix AM, Heimer EP, Gillesen D, Nardin EH, Nussenzweig RS, Nussenzweig V, Hollingdale MR, Levine MM. Safety and immunogenicity in man of a synthetic peptide malaria vaccine Against Plasmodium falciparum sporozoites. Nature 1987;328:257-259.

Herrington DA, Clyde DF, Murphy JR, Baqar S, Levine MM, do Rosario V, Hollingdale MR. A model for Plasmodium falciparum sporozoite challenge and very early therapy of parasitaemia for efficacy studies of sporozoite vaccines. Tropical Geog. Med. 1988;40:124-127.

Levine MM, Herrington DA, Clyde D, Murphy J, Davis J, Nussenzweig R, Nardin E, Felix A, Heimer E, Gillesen D, Baqar S, Hollingdale M, Nussenzweig V. Malaria vaccines: experience with sporozoite vaccines against falciparum malaria. SE Asian J. Trop. Med. Pub. Hlth. 1988;19:360-374.

Davis JR, Murphy JR, Baqar S, Clyde DF, Herrington DA, Levine MM. Estimate of anti-Plasmodium falciparum sporozoite activity in humans vaccinated with synthetic circumsporozoite protein (NANP)3. Trans Royal Soc Trop Med and Hygiene 1989;83:748-750.

DiJohn D, Wasserman SS, Torres JR, Cortesia MJ, Murillo J, Losonsky GA, Herrington DA, Sturchler D, Levine MM. Effect of priming with carrier on response to conjugate vaccine. Lancet, 1989;ii:1415-1418.

Nardin EH, Herrington DA, Davis JR, Levine M, Stuber D, Takacs B, Caspers P, Barr P, Altszuler R, Clavijo P, Nussenzweig RS. A conserved repetitive epitope is recognized by CD4+ clones from a malaria immunized volunteer. Science 1989;246:1603-1606.

Collins WE, Nussenzweig RS, Ballou WR, Ruebush II TK, Nardin EH, Chulay JD, Majarian WR, Young JF, Wasserman GF, Bathurst I, Gibson HL, Barr PJ, Hoffman SL, Wasserman SS, Broderson JR, Skinner JC, Procell PM, Filipski VK, Wilson CL. Immunization of Saimiri sciureus boliviensis with recombinant vaccines based on the circumsporozoite protein of Plasmodium vivax. Amer. J. Trop. Med. Hyg. 1989;40:455-464.

Murphy JR, Baqar S, Davis JR, Herrington DA, Clyde DF. Evidence of a 6.5-day minimum exoerythrocytic cycle for Plasmodium falciparum and confirmation that immunization with a synthetic peptide representative of the circumsporozoite protein retards infection. J. Clin. Microbiol. 1989;27:1434-1437.

Herrington DA, Clyde DF, Davis JR, Baqar S, Murphy JR, Cortese JF, Bank RS, Nardin E, DiJohn D, Nussenzweig RS, Nussenzweig V, Torres JR, Murillo J, Cortesia M, Sturchler D., Hollingdale MR, Levine MM. Human studies with synthetic peptide sporozoite vaccine (NANP)3-TT and immunization with irradiated sporozoites. Bull WHO Supplement 1990;68:33-37.

Nardin EH, Nussenzweig RS, Altszuler R, Herrington DA, Levine MM, Murphy J, Davis JR, Bathurst I, Barr P, Romero P, Zavala F. Cellular and humoral immune responses to a recombinant P. falciparum CS protein in sporozoite-immunized rodents and human volunteers. Bull WHO Supplement 1990;68:85-87.

Beier JC, Davis JR, Vaughan JA, Noden BH, Beier MS. Quantitation of Plasmodium falciparum sporozoites transmitted in vitro by experimentally infected Anopheles gambiae and Anopheles stephensi. Amer J. Trop Med. Hyg. 1991;44:564-570.

Herrington DA, Davis JR, Nardin E, Beier MS, Cortese J, Eddy H, Losonsky G, Hollingdale M, Sztein M, Levine MM, Nussenzweig R, Clyde D, Edelman R. Successful immunization of humans with irradiated sporozoites: humoral and cellular responses of the protected vaccinees. Amer J. Trop. Med. Hyg. 1991;45:539-547.

Herrington DA, Nardin EH, Losonsky G, Bathurst IC, Barr PJ, Hollingdale MR, Edelman R, Levine MM. Safety and immunogenicity of a recombinant sporozoite malaria vaccine against Plasmodium vivax. Amer. J. Trop. Med. Hyg. 1991;45:695-701.

Mellouk S, Green SJ, Nacy CA, Hoffman SL. IFN-y inhibits development of Plasmodium berghei exoerythrocytic stages in hepatocytes by an L-arginine-dependent effector mechanism. J. Immunol. 1991;146:3971-3976.

Moreno A, Clavijo P, Edelman R, Davis J, Sztein M, Herrington D, Nardin E. Cytotoxic CD4+ T cells from a sporozoite immunized volunteer recognize the Plasmodium falciparum CS protein. Inter. Immunol. 1991;3:997-1003.

Beier JC, Beier MS, Vaughan JA, Pumpuni CB, Davis JR, Noden BH. Sporozoite transmission by Anopheles freeborni and Anopheles gambiae experimentally infected with Plasmodium falciparum. J Amer Mosquito Control Assoc 1992;8:404-408.

Beier MS, Davis JR, Pumpuni CP, Noden, BH, Beier JC. Ingestion of Plasmodium falciparum sporozoites during transmission by Anopheline mosquitoes. Amer J Trop Med Hyg 1992;47:195-200.

Brown AE, Herrington DA, Webster HK, Clyde DF, Sztein MB, Davis JR, Beier MS, Edelman R. Urinary neopterin in volunteers experimentally infected with Plasmodium falciparum. Trans R Soc Trop Med Hyg 1992;86:134-136.

Davis JR, Cortese JF, Herrington DA, Murphy JR, Clyde DF, Thomas AW, Baqar S, Cochran MA, Thanassi J, Levine MM. Plasmodium falciparum: In vitro characterization and human infectivity of a cloned line. Exper Parasitol 1992;74:159-168.

Harpaz R, Edelman R, Wasserman SS, Levine MM, Davis JR, Sztein MB. Serum cytokine profiles in experimental human malaria: relationship to protection and disease course following challenge. J Clin Invest 1992;90:515-523.

Herrington DA, Losonsky GA, Smith G, Volvovitz F, Cochran M, Jackson K, Hoffman SL, Gordon DM, Levine MM, Edelman RE. Safety and immunogenicity in volunteers of a recombinant Plasmodium falciparum circumsporozoite protein malaria vaccine produced in Lepidopteran cells. Vaccine 1992;10:841-846.

Davis JR, Beier MS, Beier JC, Pumpuni CB, Edelman R, Herrington DA, Clyde DF. Evaluation of ingested human anti-sporozoite sera on Plasmodium falciparum sporogony in Anopheles stephensi. American Journal of Tropical Medicine and Hygiene, 1993, 49(2): 174-180.

Edelman, R., Hoffman, S.L., Davis, J.R., Beier, M., Sztein, M.B., Losonsky, G., Herrington, D.A., Eddy, H.A., Hollingdale, M.R., Gordon, D.M., and Clyde, D.F. Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum. J. Infect. Dis. 1993, 168:1066-1070.

Moreno A, Clavijo P, Edelman R, Davis J, Sztein M, Sinigaglia F, Nardin E. CD4+ T cell clones obtained from Plasmodium falciparum sporozoite-immunized volunteers recognize polymorphic sequences of the circumsporozoite protein. Journal of Immunology, 1993, 151(1): 489-499.

Pumpuni CB, Beier MS, Nataro JP, Davis JR. Plasmodium falciparum: Inhibition of sporogonic development in Anopheles stephensi by gram-negative bacteria. Experimental Parasitology, 1993, 77: 195-199.

Davis JR. Laboratory methods for the conduct of experimental malaria challenge of volunteers. Vaccine, 1994, 12: 321-327.

Hoffman SL, Edelman R, Bryan JP, Schneider I, Davis J, Sedegah M, Gordon D, Church P, Gross M, Silverman C, Hollingdale M, Clyde D, Sztein M, Losonsky G, Paparello S, Jones TR. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria and squalane as adjuvant. American Journal of Tropical Medicine and Hygiene, 1994, 51: 603-612.

Beier MS, Pumpuni CB, Beier JC, Davis JR. Effect of para-aminobenzoic acid, insulin, and gentamicin on Plasmodium falciparum development in anopheline mosquitoes (Diptera: Culicidae). Journal of Medical Entomology, 1994, 31: 561-565.

Plowe CV, Djimde A, Wellems TE, Diop S, Kouriba B, Doumbo OK. Community pyrimethamine-sulfadoxine use and prevalence of resistant Plasmodium falciparum genotypes in Mali: a model for deterring resistance. Am. J. Trop. Med. Hyg. 1996;55:467-471.

Church LW, Le TP, Bryan JP, Gordon DM, Edelman R, Fries L, Davis JR, Herrington DA, Clyde DF, Shmuklarsky MJ, Schneider I, McGovern TW, Chulay JD, Ballou WR, Hoffman SL. Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J. Infect. Dis. 1997;175:915-920.

Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, Carter D, Doumbo OK. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J. Infect. Dis. 1997;176:1590-6.

Cortese JF, Plowe CV. Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutations expressed in yeast. Mol. Biochem. Parasitol. 1998;94:205-14.

Djimde A, Plowe CV, Diop S, Dicko A, Wellems TE, Doumbo O. Use of antimalarial drugs in Mali: policy versus reality. Am. J. Trop. Med. Hyg. 1998;59:376-9.

Kublin JG, Witzig RS, Shankar AH, Zurita JQ, Gilman RH, Guarda JA, Cortese JF, Plowe CV. Molecular assays for surveillance of antifolate-resistant malaria. Lancet 1998;351:1629-30.

Nzila-Mounda A, Mberu EK, Sibley CH, Plowe CV, Winstanley PA, Watkins WM. Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. Antimicrob. Agents. Chemother. 1998;42:164-9.

Diourte Y, Djimde A, Doumbo OK, Sagara I, Coulibaly Y, Dicko A, Diallo M, Diakite M, Cortese JF, Plowe CV. Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali. Amer. J. Trop. Med. Hyg. 1999;60:475-8.

Watkins WM, Mberu EK, Winstanley PA, Plowe CV. More on 'the efficacy of antifolate antimalarial combinations in Africa'. Parasitol Today. 1999;15:131-2.

Agarwal A, Guindo A, Cissoko Y, Taylor JG, Coulibaly D, Kone A, Kayentao K, Djimde A, Plowe CV, Doumbo O, Wellems TE, Diallo D. Hemoglobin C associated with protection from severe malaria in the Dogon of Mali, a West African population with a low prevalence of hemoglobin S. Blood 2000, 96:2358-63.

Doumbo OK, Kayentao K, Djimde A, Cortese JF, Diourte Y, Konare A, Kublin JG, Plowe CV. Rapid selection of Plasmodium falciparum dihydrofolate reductase mutants by pyrimethamine prophylaxis. J Infect Dis. 2000, 182:993-6.

Vasconcelos KF, Plowe CV, Fontes CJ, Kyle D, Wirth DF, Pereira da Silva LH, Zalis MG. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase of isolates from the Amazon region of Brazil. Mem Inst Oswaldo Cruz. 2000,Sep- 95:721-8.

Djimde A, DoumboO, Cortese J, Kayento K, Doumbo S, Diourte Y, Dicko A, Su X, Nomura T, Fidock DA, Wellems TE, Plowe CV. A molecular marker for chloroquine-resistant falciparum malaria. New England Journal of Medicine. 2001, 344:257-263.

Gomez-Duarte O, Pasetti MF, Santiago A, Stzein MB, Hoffman SL, Levine MM. Expression, extracellular secretion, and immunogenicity of the Plasmodium falciparum sporozoite surface protein 2 in Salmonella vaccine strains. Infection and Immunity. 2001, 69:1192-1198.

Plowe CV, Doumbo OK, Djimde A, Kayentao K, Diourte Y, Doumbo SN, Coulibaly D, Thera M, Wellems TE, and Diallo DA. Chloroquine treatment of uncomplicated Plasmodium falciparum malaria in Mali: parasitologic resistance versus therapeutic efficacy. American Journal of Tropical Medicine & Hygiene. 2001, 64:242-246.

Iyer JK, Milhous WK, Cortese JF, Kublin JG, Plowe CV. Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. The Lancet. 2001, 358:1066-1067.

Djimde A, Doumbo OK, Steketee RW, Plowe CV. Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. The Lancet. 2001, 358:890-891.

Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. Journal of Infectious Diseases. 2002, 185:380-388.

Kublin JG, Lowitt MH, Hamilton RG, Oliveira GA, Nardin EH, Nussenzweig RS, Schmeckpeper BJ, Diggs CL, Bodison SA, Edelman R. Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparium sporozoites. Vaccine. 2002, 20:1853-1861.